ACM
RVMD icon

AlphaCrest Capital Management’s Revolution Medicines RVMD Stock Holding History

AlphaCrest Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,709
Closed -$408K – 931
2022
Q3 		$408K Buy
+20,709
New +$455K 0.02% 1053
2021
Q3 		– Sell
-22,500
Closed -$714K – 1363
2021
Q2 		$714K Buy
+22,500
New +$785K 0.03% 812

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlphaCrest Capital Management's RVMD Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Revolution Medicines (RVMD) in Q4 2022, closing a stake of 20,709 shares — an estimated $408K sold.

AlphaCrest Capital Management first reported a position in RVMD in Q2 2021 and held it in 2 quarters. The position peaked at $714K in Q2 2021. 135 funds tracked by Wall St. Rank hold RVMD as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Revolution Medicines position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 20,709 Revolution Medicines shares in Q4 2022, an estimated $408K.
  • AlphaCrest Capital Management first reported a position in Revolution Medicines in Q2 2021 and held it in 2 quarters.
  • AlphaCrest Capital Management's Revolution Medicines position peaked at $714K in Q2 2021.
  • 135 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.